Platelet glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions: a pharmacological and clinical review

Author： Anne Ganeshkumar Gruberg Luis

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.2, 2004-02, pp. : 335-348

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimal Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Patients Undergoing Percutaneous Coronary Interventions

By Starnes H. Benjamin Patel Ankit A. Stouffer George A.

Drugs, Vol. 71, Iss. 15, 2011-10 ,pp. : 2009-2030

Adis International

Access to resources Recommend Favorite

Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Intervention: Focus on the Pharmacokinetic-Pharmacodynamic Relationships of Eptifibatide

By Gilchrist I.C.

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 703-720

Adis International

Access to resources Recommend Favorite

Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes

Heart Drug, Vol. 1, Iss. 2, 2004-11 ,pp. : 103-109

Karger

Access to resources Recommend Favorite

Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention?

By Doggrell Sheila

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 8, 2003-08 ,pp. : 1431-1433

Informa Healthcare

Access to resources Recommend Favorite

Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors: In the Management of Acute Coronary Syndromes

By Bosanquet N.

PharmacoEconomics, Vol. 21, Iss. 16, 2003-01 ,pp. : 1135-1152

Adis International

Access to resources Recommend Favorite